Nanovibronix Inc Stock Price, News & Analysis

NanoVibronix (NASDAQ: NAOV) has secured an agreement with an upstate New York hospital to provide two ENvue™ Navigation Systems for enteral feeding tube placement. The FDA-cleared systems, expected for delivery in Q3 2025, utilize electromagnetic technology for real-time visualization during tube placement.

The agreement marks ENvue's first formal system adoption in the northeastern U.S., following recent commercial activity in the southeast. The company recently received a U.S. patent for electromagnetic navigation in pediatric feeding, supporting its broader product development strategy.

NanoVibronix's ENvue Medical division has secured U.S. Patent No. 12,324,632 for its pediatric feeding tube guidance system. The patented technology uses electromagnetic tracking for real-time feeding tube placement visualization, reducing reliance on X-rays. The system targets a significant U.S. market opportunity exceeding $150 million annually, serving approximately 400,000 preterm infants and additional pediatric patients requiring feeding tube placement, totaling over 1.5 million procedures yearly. Currently FDA-cleared for adult use only, ENvue Medical is preparing to pursue FDA 510(k) clearance for pediatric applications. The patent strengthens the company's intellectual property portfolio and demonstrates its commitment to innovation in feeding tube placement technologies.

NanoVibronix announced the immediate retirement of CEO Brian Murphy, who will remain as a director on the Board. Doron Besser, CEO of ENvue Medical Holdings (a subsidiary acquired by NanoVibronix in February 2025), has been appointed as the new CEO. The leadership transition follows NanoVibronix's strategic acquisition of ENvue, a company specializing in enteral feeding solutions. The merger aimed to combine strengths and create synergies in the medical device market. Chairman Christopher Fashek praised Murphy's contributions in driving product innovation and expanding distribution. Besser expressed optimism about capitalizing on new market opportunities and enhancing the product portfolio post-merger. The company remains focused on commercializing existing technologies while developing innovative medical solutions.

NanoVibronix (NASDAQ: NAOV) has issued an official statement denying false information circulated by Flash Alert and FintelAlerts regarding a purported $26 million registered direct offering of common stock. The alleged offering was falsely reported to be priced at $0.45 under Nasdaq rules. The company explicitly stated that it has not priced and is not consummating any registered direct offering. NanoVibronix is actively investigating this misinformation and plans to take necessary actions to protect its stockholders and reputation.

NanoVibronix (NASDAQ: NAOV) announced that a major 420-bed acute care hospital in New Orleans has selected its ENvue™ Navigation Platform for feeding tube procedures. The hospital will transition from traditional blind insertions to the FDA-cleared electromagnetic guidance system, which enables real-time visualization of tube direction and positioning during placement.

The ENvue System has already been shipped to the facility, with on-site implementation scheduled soon. This marks ENvue Medical's first entry into the Louisiana market, with additional hospital implementations being prepared across multiple U.S. regions.

NanoVibronix (NASDAQ: NAOV), a medical technology company, has closed its public offering of 400,000 shares of Series G Convertible Preferred Stock and Warrants, raising $10 million in gross proceeds. The offering included Preferred Stock at $25 per share and Warrants to purchase up to 4,901,982 common shares at $2.04 per share.

Key terms include 9% cumulative dividends on Preferred Stock payable in up to 2,205,883 common shares, and five-year Warrants exercisable immediately. The company plans to use proceeds to redeem a $1.3 million debenture from February 2025, partially repay a $2.497 million note from January 2025, and for general corporate purposes. Dawson James Securities served as the sole bookrunning manager.

NanoVibronix (NASDAQ: NAOV), a medical technology company, has announced the pricing of a $10 million public offering consisting of approximately 400,000 shares of Series G Convertible Preferred Stock and Warrants. Each unit, priced at $25.00, includes Preferred Stock and Warrants to purchase up to 4,901,961 common shares at an exercise price of $2.04 per share.

The offering, managed by Dawson James Securities, is expected to close around May 19, 2025. The company plans to use the proceeds to redeem $1.3 million in outstanding debentures, allocate $700,000 for partial repayment of a $2.49 million note, with the remainder for general corporate purposes.

NanoVibronix (NASDAQ: NAOV) has released promising results from a retrospective case series evaluating their UroShield™ system at University Hospitals Coventry and Warwickshire Partnership NHS. The study, conducted between September 2023 and January 2025, demonstrated significant clinical benefits including a 94% reduction in catheter-associated urinary tract infections (CAUTIs) and catheter blockages, and a 92% decrease in unplanned hospital visits. The UroShield device, which uses Surface Acoustic Wave (SAW) technology to prevent bacterial colonization on urinary catheters, showed high patient compliance and satisfaction. Only one patient discontinued use due to worsening pre-existing symptoms. These results align with previous studies by Markowitz et al. (2018) and Da Silva et al. (2021), further validating the device's effectiveness. The findings will be presented at the ACP 2025 conference on May 19, 2025.

NanoVibronix (NASDAQ: NAOV), a medical technology company focused on non-invasive therapeutic devices, has successfully regained full compliance with Nasdaq listing requirements. The company received formal notification from Nasdaq on April 9, 2025, confirming it has met all criteria for continued listing on The Nasdaq Capital Market, including the critical $1.00 bid price and $2.5 million stockholders' equity requirements.

The previously disclosed listing concern has been resolved, though the company will remain under a Mandatory Panel Monitor until April 9, 2026.